Name
GS3-01 - Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative BC or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy. (China)
Date & Time
Friday, December 20, 2024
Speakers
Virtual Session Link